Table 8.

Adverse Events with Pregabalin Treatment

Adverse events in clinical trials of pregabalin

The most common adverse events are dizziness (24.3% of patients) and somnolence (15.1%)

4% of patients withdraw from clinical trials due to dizziness

1.9% due to somnolence

The majority of instances of dizziness and somnolence emerge within the first 1 to 2 weeks of treatment

The majority of instances of dizziness and somnolence resolve within 1 to 2 weeks

Most adverse events are transient and resolve prior to the end of the study

Most adverse events are mild or moderate in severity3,20

Patients with a lower baseline body mass index are more likely to gain weight12

Managing adverse events with pregabalin

Carefully titrate pregabalin to the highest tolerable dose (a minimum of 150 mg/day6,27)

The initial dose, and any dose increase, should be given at night

To set expectations, potential AEs should be discussed with the patient ahead of treatment